Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kaken Grabs Japan Rights to Arbor’s Head Lice Drug
Kaken Pharmaceutical will develop Arbor Pharmaceuticals’ head lice treatment ivermectin, sold as Sklice Lotion 0.5% in the US, in Japan as strains of the parasite resistant to existing non-prescription drugs are spreading in the country, particularly in Okinawa. The Japanese…
To read the full story
Related Article
- Kaken Files Head Lice Treatment in Japan
June 8, 2026
- Kaken’s Head Lice Lotion Hits PIII Goal, Filing Eyed in 1st Half of FY2026
December 9, 2025
BUSINESS
- Argenx Steps Up Japan Hunt for Drug Discovery Seeds
October 7, 2026
- Fujifilm Adds Linker-Payload Capacity to Build One-Stop ADC CDMO Service
October 7, 2026
- Asahi Kasei Therapeutics Reports Potential Data Breach Affecting 560,000
October 7, 2026
- Toho Files Objection to Court Block on Takeover Defense Move
October 7, 2026
- Keytruda Marks 3 Years at No. 1 in September: Encise
October 7, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…